Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
Investors can watch the Sept. 2026 management webcast fireside chats live and later via replays on Lexeo’s investor website Events & Presentations page.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexeo Therapeutics (LXEO) will participate in two investor conferences in September 2026, featuring webcast fireside chats with management in New York.
The company joins the Cantor Global Healthcare Conference 2026 on September 9, 2026 at 2:10 p.m. ET and the Baird 2026 Global Healthcare Conference on September 15, 2026 at 11:25 a.m. ET. Live webcasts and replays will be accessible via the Events & Presentations section of Lexeo’s investor website.
Details
News Market Reaction – LXEO
On Sep 2, the day this news came out, LXEO closed 1.70% above the previous close. Argus tracked a trough of -16.0% from its starting point during tracking. Our momentum scanner recorded 4 alerts for this stock that day. Relative volume reached 2.8x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September:
Cantor Global Healthcare Conference 2026. Fireside chat on Wednesday, September 9, 2026 at 2:10 p.m. ET in New York, NY.
Baird 2026 Global Healthcare Conference. Fireside chat on Tuesday, September 15, 2026 at 11:25 a.m. ET in New York, NY.
The events will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcasts will be available on the Lexeo website following the presentations.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.